FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced November 4, 2025
Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma October 29, 2025
Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002 October 29, 2025
Positive Data from Ongoing Ph 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers Reported October 29, 2025
Positive Topline Results from Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Reported and Updates Provided on CRC and Ewing Sarcoma Expansion Cohorts October 29, 2025
Interim Petosemtamab Data in Metastatic CRC Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety October 29, 2025
Positive Ph 2 Results for HBM4003 and Tislelizumab Combination in MSS mCRC announced October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
FDA Fast Track Designation for NG-350A for the Treatment of MMR-Proficient Locally Advanced Rectal Cancer October 18, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Ph 3 Trial of HANSIZHUANG + Chemo Meets Primary Endpoint in Neoadjuvant/ Adjuvant Gastric Cancer, Greenlighting Early NDA Submission October 16, 2025
FDA Fast Track Designation for NG-350A for the Treatment of Mismatch Repair-Proficient Locally Advanced Rectal Cancer October 15, 2025
FAILED TRIAL: Zolbetuximab Ph 2 GLEAM Trial Did Not Meet Primary Endpoint of OS in Patients with Metastatic Pancreatic Cancer October 15, 2025
OPTIMIZE-1 biomarker analysis published in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer October 15, 2025
ONO-4578, Opdivo and Chemo combo Met the Primary Endpoint in Ph 2 Trial in Patients with 1L HER2-neg recurrent Gastric Cancer October 15, 2025
AlphaMedix™ (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in Ph 2 study in patients with GEP-NETs October 15, 2025
Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs October 15, 2025
